Immunotherapy Raises the Stakes and Ovarian Cancer Blinks – Genetic Engineering & Biotechnology News
News-Medical.net |
Immunotherapy Raises the Stakes and Ovarian Cancer Blinks
Genetic Engineering & Biotechnology News “I’ll see your neoepitope and raise you a tumor-infiltrating lymphocyte.” Such bets could be placed more confidently if cancer immunotherapy would deal itself a stronger hand, one that would include the “juiciest” T cells—the T cells that are best at … Ludwig researchers extend potential for personalized immunotherapy to ovarian cancer, other tumorsNews-Medical.net |
Xconomy |
Xconomy: Arcus Bio Pulls Off IPO, Raises $120M for Cancer …
Xconomy Arcus Biosciences has raised $120 million from an initial public offering as the cancer immunotherapy developer looks ahead to reporting its first clinical. Cancer-fighting Arcus (NYSE: RCUS), backed by Alphabet’s GV …San Francisco Business Times |
The Advertiser |
“Off-The-Shelf” Third Party T Cells for CAR-T Therapy Under Investigation
Cancer Network A matched donor with similar immunity is not required and neither are the patient’s own T cells. “We were able to efficiently (> 90%) delete both copies of CD7 and the T-cell receptor alpha subunit (TRAC) and insert a unique CAR to CD7 in human T cells … Adelaide’s Carina Biotech makes killer cells to cure cancerThe Advertiser |